Clinical Trials Logo

Elevated Lipoprotein(a) clinical trials

View clinical trials related to Elevated Lipoprotein(a).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03426033 Completed - Clinical trials for Cardiovascular Diseases

Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin

Start date: December 15, 2017
Phase: Phase 1
Study type: Interventional

This is a single center, open label, single sequence, two-treatment, two-period drug-drug interaction study to evaluate the effect of multiple doses of ISIS 681257 on the pharmacokinetics of a single dose of warfarin.

NCT ID: NCT03392051 Completed - Clinical trials for Cardiovascular Diseases

Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel

Start date: December 28, 2017
Phase: Phase 1
Study type: Interventional

This is a single center, open label, single sequence, two treatment, two-period drug-drug interaction study to evaluate the effect of multiple doses of ISIS 681257 on the pharmacokinetics of multiple doses of clopidogrel

NCT ID: NCT03070782 Completed - Clinical trials for Cardiovascular Disease

Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease

Start date: March 7, 2017
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 681257 and to assess the efficacy of different doses and dosing regimens of ISIS 681257 for reduction of plasma Lipoprotein(a) [Lp(a)] levels in participants with hyperlipoproteinemia(a) and established cardiovascular disease (CVD).

NCT ID: NCT02414594 Completed - Clinical trials for Elevated Lipoprotein(a)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)

Start date: April 2015
Phase: Phase 1
Study type: Interventional

The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS APO(a)-LRx (ISIS 681257) given to healthy volunteer subjects.

NCT ID: NCT02160899 Completed - Clinical trials for Elevated Lipoprotein(a)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a)

Start date: June 2014
Phase: Phase 2
Study type: Interventional

The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ISIS-APO(a)Rx given to participants with high lipoprotein(a) for 12 weeks.